HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults

Walter Reed Army Institute of Research (WRAIR)36 enrolled

Overview

The purpose of this study is to determine the best way to administer the candidate HIV vaccine, ALVAC HIV-1 (vCP205).

Healthy adult volunteers are assigned randomly to either a vaccine or placebo group. Injections are received either intramuscularly, intradermally, or by delivery under the skin of the volunteer's own white blood cells which have had dendritic cell reinfusion. Volunteers are vaccinated at 0, 1, 3, and 6 month time points. Volunteers are closely monitored for 1 hour after vaccination and keep a diary of symptoms for 1 week post-immunization. Volunteers undergo leukopheresis at the start of the study and after the last vaccination at Walter Reed Army Medical Center. Volunteers receive compensation benefits.

Study Type

INTERVENTIONAL

Purpose

PREVENTION

Enrollment

Conditions

HIV Infections HIV Seronegativity

Interventions

ALVAC-HIV MN120TMG (vCP205)BIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria Volunteers may be eligible for this study if they: * Are legal US residents. * Are healthy adults from 18 to 55 years of age. Exclusion Criteria Volunteers will not be eligible for this study if they: * Are HIV-positive. * Are at highest risk for HIV infection. * Are pregnant or breast-feeding. * Are allergic to eggs or neomycin. * Use certain prescription medications.

Locations (1)

Walter Reed Army Institute of Research (WRAIR)

Rockville, Maryland, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.